loading page

IMPLEMENTATION OF A FORMALIZED EVALUATION AND PLANNING TOOL TO IMPROVE PEDIATRIC ONCOLOGY OUTCOMES IN KENYA
  • +9
  • Jaime Libes,
  • Doreen Mutua,
  • Ayomide Omotola,
  • Miguel Bonilla,
  • Nickhill Bhakta,
  • Paola Friedrich,
  • David Wata,
  • Sarah Nyaboke O-Muma,
  • Michael Ganey,
  • Carol Muriithi,
  • Martin Mwangi,
  • Alfred Karagu Maina
Jaime Libes
University of Illinois Chicago College of Medicine at Peoria Department of Internal Medicine

Corresponding Author:[email protected]

Author Profile
Doreen Mutua
Gertrude Children’s Hospital
Author Profile
Ayomide Omotola
St Jude Children's Research Hospital Department of Oncology
Author Profile
Miguel Bonilla
St Jude Children's Research Hospital Department of Oncology
Author Profile
Nickhill Bhakta
St Jude Children's Research Hospital Department of Oncology
Author Profile
Paola Friedrich
St Jude Children's Research Hospital Department of Oncology
Author Profile
David Wata
Kenyatta National Hospital
Author Profile
Sarah Nyaboke O-Muma
AIC Kijabe Hospital
Author Profile
Michael Ganey
Tenwek Hospital
Author Profile
Carol Muriithi
Gertrude Children’s Hospital
Author Profile
Martin Mwangi
Kenya Ministry of Health
Author Profile
Alfred Karagu Maina
Kenya Ministry of Health
Author Profile

Abstract

Survival from pediatric cancers in low-middle-income countries is often very low compared to that of high-income countries due to multifactorial etiologies, including late presentation, delayed diagnosis, difficulty with accessing health care, drug unavailability and treatment abandonment. The St. Jude Pediatric Oncology Facility Integrated Local Evaluation Tool (PrOFILE) was developed to identify the strengths and weaknesses of individual institutions, as well as whole countries. Following the completion of data analysis from Kenyan institutions, the first PrOFILE hybrid in-person and virtual workshop was held. Multi-disciplinary stakeholders prioritized recommendations for improving care and developed smart objectives to accomplish identified goals over the following 2 years. Strengths and weaknesses of conducting a hybrid global workshop were identified.
27 Dec 2022Submitted to Pediatric Blood & Cancer
27 Dec 2022Submission Checks Completed
27 Dec 2022Assigned to Editor
27 Dec 2022Review(s) Completed, Editorial Evaluation Pending
02 Jan 2023Reviewer(s) Assigned
22 Jan 2023Editorial Decision: Revise Minor
24 Apr 2023Submission Checks Completed
24 Apr 2023Assigned to Editor
24 Apr 20231st Revision Received
24 Apr 2023Review(s) Completed, Editorial Evaluation Pending
24 Apr 2023Reviewer(s) Assigned
15 May 2023Editorial Decision: Revise Minor
25 Jul 2023Submission Checks Completed
25 Jul 2023Assigned to Editor
25 Jul 20232nd Revision Received
01 Aug 2023Review(s) Completed, Editorial Evaluation Pending
03 Aug 2023Reviewer(s) Assigned
24 Aug 2023Editorial Decision: Accept